RE: Buy high, primary endpoint met and then sell low - is this a new thing?6 Apr 2022 14:14
From IR
"The primary endpoint of Part B, clinical benefit in >3 patients out of up to 30 in each tumor type group, was set in partnership with MSD. As previously communicated, the combination of MRx0518 + pembrolizumab has now achieved the primary endpoint in the renal cell carcinoma group. We would like to clarify that the study remains open and continues to enrol, including into the RCC group as well as other tumor types. Therefore, we may end up seeing more than the current 4/16 patients with clinical benefit reported for RCC, however we have already achieved the threshold of the primary endpoint for Part B in RCC."